Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.15M | $27.8M | $7.03M | $6.75M | $6.70M | $5.40M | $18.1M | $1.92M | $441K | $59.0K |
| Revenue growth | — | 2312.3% | -74.7% | -4.0% | -0.8% | -19.4% | 234.4% | -89.3% | -77.1% | -86.6% |
| Operating income | -$16.1M | $13.9M | -$35.4M | -$16.1M | -$72.8M | -$82.1M | -$37.4M | -$27.4M | -$68.5M | -$72.9M |
| Operating margin | -1394.6% | 49.9% | -503.4% | -239.1% | -1087.4% | -1521.6% | -207.4% | -1421.6% | -15535.6% | -123601.7% |
| Net income | -$16.5M | $11.9M | -$40.1M | -$16.1M | -$63.5M | -$84.4M | -$41.7M | -$31.5M | -$35.1M | -$78.3M |
| Net margin | -1428.6% | 42.7% | -569.9% | -238.1% | -947.9% | -1563.1% | -230.8% | -1639.5% | -7965.8% | -132642.4% |
| EPS (diluted) | -$1.87 | $0.42 | -$1.20 | — | — | — | -$1,063.00 | -$113.58 | -$20.91 | -$5.84 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14.6M | $12.6M | -$3.13M | -$19.1M | -$40.5M | -$70.9M | -$26.8M | -$30.7M | -$49.1M | -$51.5M |
| Capital expenditures | $34.9K | $23.3K | $564K | $262K | $63.0K | $113K | $95.0K | — | — | — |
| Free cash flow | -$14.6M | $12.6M | -$3.69M | -$19.4M | -$40.6M | -$71.0M | -$26.8M | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $5.13M | $2.47M | $10.6M | $3.61M | $18.9M | $54.6M | $13.2M | $7.42M | $135M | $15.9M |
| Total assets | $5.77M | $42.8M | $70.3M | $36.1M | $43.8M | $80.2M | $33.4M | $21.0M | $151M | $116M |
| Total liabilities | $5.56M | $14.9M | $49.3M | $15.1M | $19.2M | $57.1M | $44.3M | $13.7M | $17.7M | $33.4M |
| Long-term debt | $0.00 | $0.00 | $14.3M | — | — | — | — | — | — | — |
| Shareholders' equity | $207K | $27.9M | $20.9M | $21.0M | $24.6M | $23.1M | -$10.9M | $7.30M | $133M | $83.0M |
| Retained earnings | -$70.0M | -$58.2M | -$98.2M | -$114M | -$178M | -$262M | -$304M | -$335M | -$370M | -$449M |
| Shares (wtd avg diluted) | 8.83M | 18.8M | 34.8M | 44.4M | 75.0M | 9.40M | 39.2B | 278K | 7.50M | 13.4M |
Every figure is extracted from Avalo Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.